- Home
- Publications
- Publication Search
- Publication Details
Title
A tale of two antibodies: obinutuzumab versus
rituximab
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 182, Issue 1, Pages 29-45
Publisher
Wiley
Online
2018-05-10
DOI
10.1111/bjh.15232
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom
- (2018) Richa Sinha et al. Clinical Lymphoma Myeloma & Leukemia
- Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis
- (2017) Yougen Wu et al. Hematology
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
- (2017) Umberto Vitolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
- (2017) Gustaaf W. van Imhoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells
- (2017) Sladjana Skopelja-Gardner et al. JOURNAL OF IMMUNOLOGY
- Which Anti-CD20 Antibody Is Better in Follicular Lymphoma?
- (2017) James O. Armitage et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era
- (2017) Eamonn S. Molloy et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Cost‐Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy
- (2017) Ana Teresa Paquete et al. Applied Health Economics and Health Policy
- Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
- (2017) M. Pfreundschuh et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation
- (2016) Kazumi Hayashi et al. CANCER SCIENCE
- Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system
- (2016) Dennis W. Raisch et al. Expert Opinion On Drug Safety
- Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands
- (2016) Hedwig M. Blommestein et al. LEUKEMIA RESEARCH
- Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy
- (2016) Ursula Becker et al. VALUE IN HEALTH
- Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12
- (2016) H S Walter et al. Blood Cancer Journal
- Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
- (2015) C. L. Freeman et al. BLOOD
- Obinutuzumab in hematologic malignancies: Lessons learned to date
- (2015) Tim Illidge et al. CANCER TREATMENT REVIEWS
- Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
- (2015) G. Cartron et al. HAEMATOLOGICA
- Tumor-associated macrophages in diffuse large B-cell lymphoma
- (2015) R. Kridel et al. HAEMATOLOGICA
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- (2015) Carla Casulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
- (2015) Peter Hillmen et al. LANCET
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
- (2015) V Goede et al. LEUKEMIA
- Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
- (2015) L Ysebaert et al. Blood Cancer Journal
- Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
- (2015) G. Cartron et al. HAEMATOLOGICA
- Tumor-associated macrophages in diffuse large B-cell lymphoma
- (2015) R. Kridel et al. HAEMATOLOGICA
- Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro
- (2015) Jennifer D. Könitzer et al. PLoS One
- Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL
- (2014) N. Murawski et al. ANNALS OF ONCOLOGY
- Fc -receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
- (2014) R. P. Taylor et al. BLOOD
- Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
- (2014) S. Riihijarvi et al. HAEMATOLOGICA
- Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group
- (2014) Michael Pfreundschuh et al. JOURNAL OF CLINICAL ONCOLOGY
- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
- (2014) Liat Binyamin et al. JOURNAL OF IMMUNOLOGY
- KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity
- (2014) G. Terszowski et al. JOURNAL OF IMMUNOLOGY
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
- (2014) J. Du et al. Cancer Immunology Research
- Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
- (2013) J. Golay et al. BLOOD
- At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity
- (2013) Anne Danielou-Lazareth et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Gilles A. Salles et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties
- (2013) S. Rafiq et al. JOURNAL OF IMMUNOLOGY
- New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor
- (2013) Tim M. Illidge et al. LEUKEMIA & LYMPHOMA
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
- (2013) Christian Klein et al. mAbs
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
- (2013) S. Herter et al. MOLECULAR CANCER THERAPEUTICS
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
- (2012) L. H. Sehn et al. BLOOD
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
- (2012) C. Muller et al. BLOOD
- Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
- (2012) U. Jager et al. HAEMATOLOGICA
- Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia
- (2012) Jing Li et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
- (2012) F. J. Beurskens et al. JOURNAL OF IMMUNOLOGY
- Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia
- (2012) Emilie Laprevotte et al. LEUKEMIA RESEARCH
- Rituximab resistance
- (2011) Andrew R. Rezvani et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
- (2011) Madhavi Challa-Malladi et al. CANCER CELL
- Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies
- (2011) G. Cartron et al. CLINICAL CANCER RESEARCH
- rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
- (2011) X. Ge et al. CLINICAL CANCER RESEARCH
- IL-6/IL-6 receptor system and its role in physiological and pathological conditions
- (2011) Masahiko Mihara et al. CLINICAL SCIENCE
- The predictive significance of CD20 expression in B-cell lymphomas
- (2011) Veronika Prevodnik et al. Diagnostic Pathology
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Fc-Gamma-Receptor IIIa Polymorphism and Gene Expression Profile Do Not Predict the Prognosis in Diffuse Large B-cell Lymphoma Treated with R-CHOP Protocol
- (2011) László Váróczy et al. PATHOLOGY & ONCOLOGY RESEARCH
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia
- (2010) Wei Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
- (2010) Marinus H.J. van Oers et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
- (2010) M Le Garff-Tavernier et al. LEUKEMIA
- The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study
- (2010) Joseph J. Sacco et al. PLoS One
- Antigenic Modulation and Rituximab Resistance
- (2010) Ronald P. Taylor et al. SEMINARS IN HEMATOLOGY
- Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
- (2009) J. Hiraga et al. BLOOD
- CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
- (2009) N. A. Johnson et al. HAEMATOLOGICA
- Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression
- (2008) S. H. Olejniczak et al. CLINICAL CANCER RESEARCH
- Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
- (2008) M. S. Czuczman et al. CLINICAL CANCER RESEARCH
- Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling
- (2008) Claire A. Walshe et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started